Catherine E. Owen - Mar 24, 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Chief Executive Officer, Director
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Mar 24, 2025
Transactions value $
$0
Form type
4
Date filed
3/26/2025, 07:49 PM
Previous filing
Sep 25, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +320K $0.00 320K Mar 24, 2025 Common Stock 320K $17.23 Direct F1
transaction ACAD Restricted Stock Units Award $0 +94K $0.00 94K Mar 24, 2025 Common Stock 94K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 24, 2026.